8-K: SBC Medical Q3 Profit Soars 353% Amid Revenue Dip

SBC Medical Group Holdings reported a significant 353% increase in Q3 2025 net income to $13 million, despite an 18% year-over-year revenue decrease to $43 million, driven by business restructuring and cost optimization.

Summary

• Total revenues for Q3 2025 decreased by 18% year-over-year to $43 million, primarily due to franchise fee revisions and business restructuring initiatives.
• Net income attributable to SBC Medical Group Holdings Incorporated for Q3 2025 surged by 353% year-over-year to $13 million.
• Earnings per share (EPS) for Q3 2025 increased to $0.12, compared to $0.03 in the same period of 2024.
• EBITDA for Q3 2025 rose by 12% year-over-year to $17 million, with EBITDA margin improving to 38% from 28% in Q3 2024.
• The number of franchise locations grew by 34 to 258 as of September 30, 2025.
• The number of customers in the last twelve months increased by 14% year-over-year to 6.5 million, with a 72% repeat rate.
• Year-to-date 2025 revenues were $134 million, a 17% decrease, while year-to-date net income was $37 million, an 8% decrease.
• The company announced a tender offer to acquire a majority stake in Waqoo,Inc. (TSE Growth:4937) at JPY 1,900 per share, with the offer period from November 14, 2025, to December 12, 2025.
• SBC Medical is expanding into Thailand, partnering with BLEZ ASIA, to enter the rapidly growing aesthetic medical market.

Sentiment

Score: 7

Explanation: While revenue declined due to restructuring, the significant increase in Q3 net income and EBITDA, driven by cost optimization, is a strong positive. Strategic expansions and acquisitions indicate future growth potential. However, the year-to-date revenue and profit declines, along with low share liquidity, temper the overall sentiment.

Positives

• Net income attributable to SBC Medical Group Holdings Incorporated increased by 353% year-over-year to $13 million in Q3 2025.
• Income from operations increased by 15% year-over-year to $16 million in Q3 2025.
• EBITDA increased by 12% year-over-year to $17 million in Q3 2025, with EBITDA margin improving to 38% from 28%.
• Return on equity significantly increased by 17 percentage points year-over-year to 23% in Q3 2025.
• The number of franchise locations grew by 34 to 258 as of September 30, 2025, representing a 15% increase.
• The number of customers in the last twelve months increased by 14% year-over-year to 6.5 million, with a strong repeat rate of 72%.
• The company maintains a robust balance sheet with $127 million in cash and cash equivalents, a 510% current ratio, and a 0.11x debt-to-equity ratio.
• Strategic expansion into the high-growth Thai aesthetic medical market through a partnership with BLEZ ASIA.
• Planned acquisition of Waqoo,Inc. to enhance clinical services, leverage R&D for new treatments, and secure a technology pillar for global expansion.

Negatives

• Total revenues decreased by 18% year-over-year to $43 million in Q3 2025.
• Year-to-date 2025 total revenues decreased by 17% year-over-year to $134 million.
• Year-to-date 2025 income from operations decreased by 17% year-over-year to $55 million.
• Year-to-date 2025 net income attributable to SBC Medical Group decreased by 8% year-over-year to $37 million.
• Year-to-date 2025 EBITDA decreased by 17% year-over-year to $57 million.
• Revenue decline was primarily driven by past business restructuring initiatives, including revision of franchise fees, deconsolidation of certain group entities, decreased procurement revenue, and lower management services revenue due to discontinuation of clinic operation staff supporting services.

Risks

• Low liquidity of shares makes it difficult for many institutional investors to trade, potentially hindering share price appreciation.
• Forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify, including changes in global, regional, or local economic, business, competitive, market, and regulatory conditions.

Future Outlook

The company aims to pursue sustainable growth towards 2026 by focusing on delivering high-quality solutions, advancing multi-brand initiatives in the dermatology segment, and building a stronger business foundation in overseas markets, particularly through new business development in Thailand and the acquisition of Waqoo,Inc. to enhance clinical services and R&D capabilities.

Management Comments

• "In Q3 2025, SBC Medicals revenue decreased by 18% year over year. This decline primarily reflects the impact of our past business restructuring initiatives, including the revision of franchise fees and the deconsolidation of certain group entities. Meanwhile, rental revenue remained solid, supported by the renewal of medical equipment, and the consolidation of AHH contributed positively to overall performance."
• "Profitability improved significantly during the quarter. Income from operations increased by 15% year over year, net profit rose by 353%, and income from operations margin strengthened to 37%. These improvements were mainly driven by the absence of IPO-related and stock-based compensation expenses recorded in the prior year, indicating that our cost structure is normalizing toward a sustainable level."
• "Looking ahead, we will continue to pursue sustainable growth toward 2026 by focusing on delivering high-quality solutions, advancing multi-brand initiatives in the dermatology segment, and building a stronger business foundation in overseas markets."

Industry Context

SBC Medical Group operates in a diverse and growing medical franchise sector, including advanced aesthetic medicine, dermatology, and other specialized fields. The strategic expansion into Thailand, a major medical tourism hub with high growth potential and a fragmented market, aligns with broader trends of internationalization and consolidation in the healthcare services industry. The acquisition of Waqoo,Inc., with its R&D capabilities, positions the company to innovate within clinical services and skincare, addressing evolving consumer demands for advanced treatments and D2C products. The focus on multi-brand initiatives in dermatology also reflects a strategy to capture various market segments within a competitive landscape.

Comparison to Industry Standards

• The company's inclusion in the Russell 3000 Index in June 2025 indicates its recognition as a significant player within the U.S. equity market, providing a broad benchmark for its performance.
• The expansion into Thailand, a market characterized by fragmented small-scale clinics and inconsistent service quality, presents an opportunity to leverage SBC Medical's established brand and service quality to gain market share, similar to how larger, more established medical groups expand into developing markets.
• The acquisition of Waqoo,Inc. to enhance R&D and clinical services, particularly in areas like AGA and orthopedics, is comparable to strategies employed by other medical and pharmaceutical companies seeking to integrate research and development with clinical application to drive innovation and market differentiation.

Related Party Transactions

• Accounts receivable related parties increased from $28,846,680 (Dec 31, 2024) to $58,585,273 (Sep 30, 2025).
• Finance lease receivables, current related parties increased from $5,992,585 (Dec 31, 2024) to $9,757,901 (Sep 30, 2025).
• Finance lease receivables, non-current related parties increased from $8,397,582 (Dec 31, 2024) to $14,709,715 (Sep 30, 2025).
• Long-term investments in MCs related parties increased from $17,820,910 (Dec 31, 2024) to $18,869,390 (Sep 30, 2025).
• Accounts payable related parties increased from $659,044 (Dec 31, 2024) to $2,842,877 (Sep 30, 2025).
• Notes and other payables, current related parties increased from $26,255 (Dec 31, 2024) to $1,637,370 (Sep 30, 2025).
• Advances from customers related parties decreased from $11,739,533 (Dec 31, 2024) to $6,957,477 (Sep 30, 2025).
• Due to related party decreased from $2,823,590 (Dec 31, 2024) to $2,791,808 (Sep 30, 2025).
• Payables to related parties in connection with loan services provided amounted to $14,362,902 for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact from significant Q3 profit growth and strategic initiatives, but negative impact from revenue decline and concerns over low share liquidity.
• Customers: Benefit from increased franchise locations, growing customer base, high repeat rates, and enhanced service offerings through multi-brand initiatives and the Waqoo acquisition.
• Employees: Potential for growth and new opportunities through international expansion and acquisitions, though past restructuring involved discontinuation of some services.
• Suppliers: Decreased procurement revenue suggests reduced orders for medical materials, potentially impacting suppliers.
• Creditors: Increased long-term loans indicate higher leverage, but a strong balance sheet with high current and capital ratios suggests good repayment capacity.

Next Steps

• Continue to pursue sustainable growth toward 2026.
• Focus on delivering high-quality solutions.
• Advance multi-brand initiatives in the dermatology segment.
• Build a stronger business foundation in overseas markets, specifically in Thailand.
• Complete the Tender Offer for Waqoo,Inc. by December 12, 2025, with settlement commencing December 19, 2025.
• Hold a conference call on November 17, 2025, to discuss financial results and take questions.

Key Dates

Recommendation

SBC Medical Group Holdings demonstrated strong profitability in Q3 2025, with net income soaring by 353% and EBITDA up 12%, primarily due to effective cost optimization and the absence of prior-year IPO-related expenses. The company's strategic moves, including expansion into Thailand and the acquisition of Waqoo,Inc., signal a clear path for future growth and diversification. However, the persistent year-over-year decline in total revenues for both Q3 and YTD 2025, attributed to business restructuring and fee revisions, remains a significant concern. Additionally, the acknowledged low liquidity of the company's shares could deter institutional investors. While the profitability improvements are commendable, the revenue headwinds and liquidity issues warrant a cautious 'hold' stance until there is clearer evidence of revenue stabilization and improved share market dynamics.

Keywords

Medical Group Holdings, Financial Results, Q3 2025, Earnings, Revenue, EBITDA, Franchise Locations, Customer Growth, Aesthetic Medicine, Dermatology, Orthopedics, Fertility Treatment, Dentistry, AGA, Ophthalmology, Thailand Expansion, Waqoo Acquisition, Tender Offer, Corporate Strategy, SEC Filing